دورية أكاديمية
أعرض في EDS

Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa .

التفاصيل البيبلوغرافية
العنوان: Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa .
المؤلفون: Muddassir M; Institute of Molecular Biology & Biotechnology (IMBB), The University of Lahore, Defence road campus, Lahore, Pakistan., Munir S; Department of Pathology, Combined Military Hospital, Lahore Cantt, Pakistan., Raza A; Institute of Molecular Biology & Biotechnology (IMBB), The University of Lahore, Defence road campus, Lahore, Pakistan., Basirat A; Department of Respiratory Medicine, Tallaght University Hospital, Dublin, Ireland., Ahmed M; M. Islam Medical College, Gujranwala, Pakistan., Farooq U; Institute of Molecular Biology & Biotechnology (IMBB), The University of Lahore, Defence road campus, Lahore, Pakistan., Ahmed SS; Al-Aleem Centre for Advanced Studies and Research, Gulab Devi Educational Complex, Lahore, Pakistan., Naqvi SZH; Institute of Molecular Biology & Biotechnology (IMBB), The University of Lahore, Defence road campus, Lahore, Pakistan.
المصدر: Iranian journal of basic medical sciences [Iran J Basic Med Sci] 2021 Oct; Vol. 24 (10), pp. 1373-1379.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Mashhad University of Medical Sciences Country of Publication: Iran NLM ID: 101517966 Publication Model: Print Cited Medium: Print ISSN: 2008-3866 (Print) Linking ISSN: 20083866 NLM ISO Abbreviation: Iran J Basic Med Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Mashhad : Mashhad University of Medical Sciences
مستخلص: Objectives: Isolates producing metallo-β-lactamase (MBL) have a significant impact on therapeutic and diagnostic layouts, plus their increased frequency has been reported globally. Determination of incidence of clinical isolates of Pseudomonas aeruginosa that are capable of producing MBL and AmpC-β-lactamases making them resistant to imipenem and cefoxitin.
Materials and Methods: Out of 1159 collected samples of urine, wound swabs, blood, tissue, and pus, the isolation rate of P. aeruginosa in the period of March 2020 to February 2021 was 22.0% (255/1159). Bacterial strains that were resistant towards imipenem were further processed for detecting the β-lactamase group of genes followed by statistical analysis of risk factors done based on clinical sample, gender, plus department of sample collection.
Results: The percentage of resistance against imipenem was found to be 53%. Out of 135 strains, phenotypic tests revealed MBLs incidence to be 61.5% by combination disc test and 81.5% by Modified Hodge test (MHT). Frequencies of blaIMP-1, blaVIM, blaSHV, blaTEM, and blaOXA genes were calculated to be 13%, 15%, 32%, 43%, and 21%, respectively. Co-expressions of blaMBLs (blaVIM and blaIMP-1) plus blaESBL (blaSHV, blaOXA, blaTEM) were detected using simplex and multiplex PCR. blaTEM, blaSHV, and blaOXA co-existed in 7.5% of clinical isolates. 5.5% of the isolates exhibited simultaneous expression of MBL/ESBL genes. 15% of the isolates resistant to cefoxitin were positive for the blaAmpC gene (17/114).
Conclusion: This is a pioneer report from Pakistan that concomitantly presents expression of blaVIM and blaIMP-1 with blaTEM, blaOXA, blaSHV, and blaAmpC in isolates of P. aeruginosa .
References: Pak J Med Sci. 2014 Sep;30(5):951-4. (PMID: 25225505)
Antimicrob Agents Chemother. 2015 Dec 07;60(2):1067-78. (PMID: 26643349)
Indian J Med Res. 2016 Nov;144(5):781-783. (PMID: 28361833)
Pak J Med Sci. 2015;31(3):561-5. (PMID: 26150844)
Antimicrob Agents Chemother. 2000 Sep;44(9):2304-9. (PMID: 10952572)
Biomed Res Int. 2014;2014:101635. (PMID: 24707471)
J Epidemiol Glob Health. 2017 Sep;7(3):155-159. (PMID: 28756823)
PLoS One. 2015 Mar 20;10(3):e0121668. (PMID: 25794144)
Microb Drug Resist. 2017 Oct;23(7):838-844. (PMID: 28191865)
J Hosp Infect. 2015 Apr;89(4):241-7. (PMID: 25737092)
Lancet Infect Dis. 2010 Sep;10(9):597-602. (PMID: 20705517)
Clin Microbiol Infect. 2010 Dec;16(12):1699-701. (PMID: 20874758)
Microb Pathog. 2017 Feb;103:8-12. (PMID: 27956216)
Microb Drug Resist. 2021 Jun;27(6):760-767. (PMID: 33211640)
Clin Microbiol Rev. 2006 Apr;19(2):403-34. (PMID: 16614255)
J Antimicrob Chemother. 2011 Sep;66(9):1998-2001. (PMID: 21693460)
Acta Med Iran. 2016 Feb;54(2):107-13. (PMID: 26997597)
Diagn Microbiol Infect Dis. 2004 Mar;48(3):167-72. (PMID: 15023424)
Ann Clin Microbiol Antimicrob. 2016 Apr 06;15:20. (PMID: 27048322)
Clin Microbiol Infect. 2016 Mar;22 Suppl 1:S9-14. (PMID: 27000156)
J Clin Microbiol. 2003 Dec;41(12):5407-13. (PMID: 14662918)
Am J Clin Pathol. 1966 Apr;45(4):493-6. (PMID: 5325707)
J Infect Chemother. 2013 Apr;19(2):330-2. (PMID: 22965842)
Clin Microbiol Infect. 2002 Jun;8(6):321-31. (PMID: 12084099)
FEMS Microbiol Lett. 2003 Jun 27;223(2):147-51. (PMID: 12829279)
Saudi J Biol Sci. 2015 Jul;22(4):424-9. (PMID: 26150748)
Euro Surveill. 2014 May 22;19(20):. (PMID: 24871756)
Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33. (PMID: 7574506)
Antimicrob Agents Chemother. 1995 Apr;39(4):824-9. (PMID: 7785978)
Clin Microbiol Infect. 2004 Aug;10(8):757-60. (PMID: 15301681)
J Pak Med Assoc. 2004 Jul;54(7):357-60. (PMID: 15449917)
J Thorac Dis. 2015 Mar;7(3):376-85. (PMID: 25922715)
FEMS Microbiol Lett. 2001 Jan 1;194(1):53-7. (PMID: 11150665)
Medicine (Baltimore). 2016 Jul;95(27):e4099. (PMID: 27399106)
Lancet Infect Dis. 2011 May;11(5):381-93. (PMID: 21530894)
Ann Lab Med. 2015 Nov;35(6):595-601. (PMID: 26354347)
Microbiol Spectr. 2016 Apr;4(2):. (PMID: 27227291)
Exp Ther Med. 2018 Jan;15(1):1143-1149. (PMID: 29399114)
J Antimicrob Chemother. 2012 Jan;67(1):234-6. (PMID: 21965430)
Curr Opin Infect Dis. 2008 Aug;21(4):367-71. (PMID: 18594288)
J Antimicrob Chemother. 2006 Mar;57(3):373-83. (PMID: 16446375)
J Infect Dev Ctries. 2010 Dec 23;4(12):810-3. (PMID: 21252461)
Antimicrob Agents Chemother. 2010 May;54(5):2219-24. (PMID: 20194693)
Braz J Microbiol. 2017 Jul - Sep;48(3):493-498. (PMID: 28291698)
Jundishapur J Microbiol. 2014 Sep;7(9):e16436. (PMID: 25485066)
Infect Control Hosp Epidemiol. 2009 Jun;30(6):543-9. (PMID: 19435448)
Clin Microbiol Infect. 2012 Sep;18(9):E362-5. (PMID: 22738206)
Lancet Glob Health. 2016 Oct;4(10):e676-7. (PMID: 27633421)
Antimicrob Agents Chemother. 2017 Mar 24;61(4):. (PMID: 28167547)
Antimicrob Agents Chemother. 2009 Dec;53(12):5046-54. (PMID: 19770275)
J Hosp Infect. 2011 Jun;78(2):143-8. (PMID: 21459477)
Indian J Med Paediatr Oncol. 2016 Jan-Mar;37(1):20-4. (PMID: 27051152)
فهرسة مساهمة: Keywords: Antibiotic resistance; Beta-Lactamases; Infections; MDR genes; Pseudomonas aeruginosa
تواريخ الأحداث: Date Created: 20220131 Latest Revision: 20240405
رمز التحديث: 20240405
مُعرف محوري في PubMed: PMC8769517
DOI: 10.22038/IJBMS.2021.57293.12748
PMID: 35096295
قاعدة البيانات: MEDLINE
الوصف
تدمد:2008-3866
DOI:10.22038/IJBMS.2021.57293.12748